Article

Aptiom FDA-Approved for New Indication

Now used as monotherapy in partial-onset seizures


 

References

Sunovion Pharmaceuticals, Inc. announced that FDA approved the supplemental New Drug Application for Aptiom (eslicarbazepine acetate) as monotherapy for the treatment of partial-onset seizures. This new approved indication allows Aption to be used as monotherapy in people who initiate treatment for the first time or convert from other antiepileptic drugs to Aptiom.

Dosage and Administration: The recommended initial dosage of Aptiom is 400 mg once daily. For some patients, treatment may be initiated at 800 mg once daily if the need for seizure reduction outweighs an increased risk of adverse reactions.

• Increase the dose in weekly increments of 400 mg to 600 mg once daily, based on clinical response and tolerability, to a recommended maintenance dosage of 800 mg to 1600 mg once daily.

• Patients with moderate or severe renal impairment: Reduce dosage by 50%.

Adverse Events: Most common adverse reactions in patients receiving Aptiom (≥4% and ≥2% greater than placebo): dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.

Citation: Sunovion announces FDA approval of a new indication for Aptiom (eslicarbazepine acetate) as monotherapy for partial-onset seizures. [news release]. Marlborough, MA: Sunovion; August 28, 2015: http://www.sunovion.com/news/pressReleases/20150828.pdf. Accessed September 2, 2015.

Recommended Reading

CMS improves Open Payments system, but not enough
MDedge Neurology
CMS pledges flexibility during first year of ICD-10
MDedge Neurology
Fee schedule update includes advance care planning, PQRS changes
MDedge Neurology
21st Century Cures bill passes House
MDedge Neurology
GAO: Undercover agents effectively scammed healthcare.gov
MDedge Neurology
AMA Town Hall: Doctors call for meaningful use delay
MDedge Neurology
Good news, bad news in the Medicare trustees report
MDedge Neurology
OpenNotes: Transparency in health care
MDedge Neurology
Caps on malpractice damages
MDedge Neurology
HHS: Expand antidiscrimination protections to transgender patients
MDedge Neurology